SCHEMBL19862563

SCHEMBL19862563

CC(C)NC(C)(C)c1ccccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
HDAC6 Q9UBN7 1/20 0.42
CYP1A2 P05177 3/20 0.40
CHRM2 P08172 1/20 0.37
IMPDH2 P12268 2/20 0.36
GPR142 Q7Z601 1/20 0.36
TDP1 Q9NUW8 3/20 0.35
CHRM3 P20309 1/20 0.35
ALDH1A1 P00352 3/20 0.35
CYP2C19 P33261 1/20 0.35
KDM4E B2RXH2 1/20 0.35
TRPM8 Q7Z2W7 2/20 0.35
MITF O75030 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
SLC22A2 O15244 1/20 0.35
SLC22A1 O15245 1/20 0.35
PGR P06401 1/20 0.35
THRB P10828 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24732551 0.84 MEN1 (0.41) SMN1; SMN2L3MBTL1HDAC6CYP1A2CHRM2
SCHEMBL2055586 0.79 SMN1; SMN2 (0.50) SMN1; SMN2L3MBTL1HDAC6CYP1A2CHRM2
SCHEMBL24449646 0.78 SMN1; SMN2 (0.48) SMN1; SMN2L3MBTL1HDAC6CYP1A2CHRM2
SCHEMBL28038463 0.75 SMN1; SMN2 (0.50) SMN1; SMN2L3MBTL1HDAC6CYP1A2CHRM2
SCHEMBL22863374 0.75 SMN1; SMN2 (0.50) SMN1; SMN2L3MBTL1CYP1A2CHRM2TDP1
SCHEMBL20809866 0.75 SMN1; SMN2 (0.50) SMN1; SMN2L3MBTL1CYP1A2CHRM2TDP1
SCHEMBL2018258 0.75 SMN1; SMN2 (0.50) SMN1; SMN2L3MBTL1CYP1A2CHRM2TDP1
SCHEMBL24451411 0.74 SMN1; SMN2 (0.45) SMN1; SMN2L3MBTL1HDAC6CHRM2IMPDH2
SCHEMBL5407259 0.74 SLC40A1 (0.40) SMN1; SMN2L3MBTL1HDAC6CYP1A2IMPDH2
SCHEMBL29080 0.73 SMN1; SMN2 (0.58) SMN1; SMN2L3MBTL1CYP1A2CHRM2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174531-A1 SATURATED SPIROCYCLICS AS ANTIVIRAL AGENTS ENANTA PHARMACEUTICALS, INC. 2023-06-08 US disclosed
US-11384090-B2 Spiropyrrolidine derived antiviral agents ENANTA PHARMACEUTICALS, INC. (US) 2022-07-12 US disclosed
US-11352363-B1 Spiropyrrolidine derived antiviral agents ENANTA PHARMACEUTICALS, INC. (US) 2022-06-07 US disclosed
US-20220162231-A1 NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS ENANTA PHARMACEUTICALS, INC. 2022-05-26 US disclosed
US-20220162217-A1 NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS ENANTA PHARMACEUTICALS, INC. 2022-05-26 US disclosed
US-20220162216-A1 NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS ENANTA PHARMACEUTICALS, INC. 2022-05-26 US disclosed
US-20180044343-A1 BICYCLIC IMIDAZOLO DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2018-02-15 US disclosed
US-20180044343-A1 BICYCLIC IMIDAZOLO DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2018-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180044343-A1 BICYCLIC IMIDAZOLO DERIVATIVE PDE3A, PDE2A, PDE5A SMN1; SMN2 2225/4885L3MBTL1 4405/4885HDAC6 111/4885
US-11384090-B2 Spiropyrrolidine derived antiviral agents ACE, ACE2, REN SMN1; SMN2 2731/4885L3MBTL1 4874/4885HDAC6 111/4885
US-20230174531-A1 SATURATED SPIROCYCLICS AS ANTIVIRAL AGENTS ACE, ACE2, PKD1 SMN1; SMN2 2188/4885L3MBTL1 4862/4885HDAC6 93/4885
US-20220162216-A1 NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS ACE, ACE2, REN SMN1; SMN2 3409/4885L3MBTL1 4870/4885HDAC6 51/4885
US-20220162217-A1 NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS ACE, ACE2, REN SMN1; SMN2 2887/4885L3MBTL1 4657/4885HDAC6 86/4885
US-20220162231-A1 NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS ACE, ACE2, PKD1 SMN1; SMN2 3361/4885L3MBTL1 4851/4885HDAC6 51/4885
US-11352363-B1 Spiropyrrolidine derived antiviral agents ACE, ACE2, REN SMN1; SMN2 1922/4885L3MBTL1 4488/4885HDAC6 179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.